Don't expect Restasis generics till at least next quarter, Allergan CEO says

Allergan CEO Brent Saunders delivered preliminary 2018 financial guidance Monday at the J.P. Morgan Healthcare Conference.

SAN FRANCISCO—Update on those Restasis generics Allergan investors have been seriously dreading: The company now believes they’re “unlikely” to arrive before the second quarter, CEO Brent Saunders says.

What that timeline in mind, Allergan’s now predicting $15 billion to $15.3 billion in revenues for the year, he said Monday at the J.P. Morgan Healthcare Conference. As for non-GAAP earnings per share, Saunders pegged it as at least $15.25. But “if Restasis comes later, that floor goes higher,” he told investors.

One other factor going into that EPS figure? A non-GAAP effective tax rate of no more than 15%, thanks to new U.S. tax reform laws.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

RELATED: Allergan loses Restasis patent protections in federal court decision

The preliminary guidance marks an update on the scenarios Saunders outlined on Allergan’s third-quarter conference call in November, just a couple of weeks after a court decision paved the way for copies of the dry eye blockbuster. The new EPS estimate is 25 cents per share higher than the most conservative projection he offered up at the time, which were based on knockoffs arriving this month.

Allergan’s hoping the new forecast can lift shareholders’ spirits; their Restasis fears were holding shares back well before the court’s verdict was even announced. Allergan itself was spooked enough about a potential generic entry to strike a controversial IP pact with the Saint Regis Mohawk Tribe that protected the med from the U.S. patent office’s inter partes review.

RELATED: Allergan chops 1,400 jobs to cope with early Restasis generics

Saunders, though, is confident they’ll come around in 2018—and if a recently unveiled cost-cutting drive doesn’t do the trick, he thinks upcoming data readouts on key pipeline products can. “There is a disconnect between our results and the stock price,” he said, adding that “I believe the true value of our business will become more obvious” this year.

Meanwhile, Allergan is also working to fend off investor concerns about forthcoming competition to Botox, its lead product. Saunders, quoting Bloomberg Businessweek, called the product a “$2.8 billion fortress,” adding that “it would take decades of heavy investment” before any potential rival could match its quality and breadth of data.

Not one to shy away from descriptors, Saunders also called the Botox brand “iconic” and characterized the overall medical aesthetics market as “still in the early stages of becoming a supernova.”

Suggested Articles

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.